Trial Profile

A phase 3 study assessing brilaroxazine in schizophrenia patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2025 According to a Reviva Pharmaceuticals media release, Initiation of registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia expected in mid-2025.
31 Mar 2025 According to a Reviva Pharmaceuticals media release, this registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025, Potential NDA submission for brilaroxazine in schizophrenia targeted for the fourth quarter of 2026
14 Nov 2024 According to a Reviva Pharmaceuticals media release, Initiation of registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia expected in Q1 2025, subject to receipt of additional financing

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com